Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralsetinib versus standard of care in first-line RET fusion-positive metastatic non-small cell lung cancer
jRCT2031210657Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Pralsetinib with Standard of care (2 arms). Primary endpoint: Progression-free survival. Started Jun 2022; status: completed.
02
Drugs
pralsetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031210657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210657.